Formoterol
Formoterol is a long-acting beta-2 adrenergic agonist with an unusually fast onset, combining LABA duration with reliever-like speed. It is used as maintenance therapy for asthma and COPD, and in maintenance-and-reliever (MART) regimens paired with an inhaled corticosteroid. Occasionally sought for physique use because of its potency, but its inhaled route and low systemic exposure make it a weak fat-loss tool relative to clenbuterol.
01 Overview
Formoterol is a potent, moderately lipophilic beta-2 agonist that acts within a few minutes yet lasts around 12 hours, giving it both a fast onset like a rescue inhaler and long duration like a controller. This dual property underpins MART regimens, where a single budesonide/formoterol inhaler is used both for maintenance and as needed for symptom relief.
In asthma, as with all LABAs, it must be combined with an inhaled corticosteroid. Formoterol is well studied with a mature safety profile. Its systemic sympathomimetic effects (tremor, palpitations, hypokalaemia) appear at higher or repeated doses. It has occasionally been misused for its beta-agonist thermogenic and anti-catabolic potential, but inhaled dosing delivers little systemic drug, and oral misuse is not a recognised safe practice.
02 Mechanism
Potent long-acting selective beta-2 agonist with rapid onset. Its moderate lipophilicity allows both fast diffusion to the receptor and a depot effect giving ~12-hour bronchodilation via increased cyclic AMP.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Maintenance | 6–12 mcg | Inhaled | 6-12 mcg once or twice daily; also used as-needed in MART regimens. |
| Daily maximum | 24–48 mcg/day | Inhaled | Upper daily limits vary by product and indication. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Rapid, sustained bronchodilationFast onset with long duration, enabling both maintenance and reliever use. | onset ~1-3 min, ~12 h duration | Clinical | |
| Reduced exacerbations (with steroid)Combined with an inhaled corticosteroid in MART regimens, reduces asthma exacerbations. | fewer flares | Clinical |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Tremor and palpitationsFine tremor, palpitations and headache, dose-dependent and usually mild at inhaled doses. | Mild | Common | Clinical | |
| TachycardiaRaised heart rate with excessive dosing; overuse of any reliever component increases cardiovascular strain. | Moderate | With overuse | Clinical | |
| HypokalaemiaIntracellular potassium shift lowering serum potassium at high or repeated doses. | Moderate | With high doses | Clinical |